Novel therapeutic options for treatment of recurrent implantation failure

Emerging evidence supports the use of promising immune treatment options to help patients suffering from recurrent implantation failure.

Like Comment
Related Content

VOLUME 116, ISSUE 6, P1449-1454


Jenna Turocy, M.D., Zev Williams, M.D., Ph.D. 


Despite the challenges in studying recurrent implantation failure, progress is currently being made in therapeutic options to help those who suffer from recurrent implantation failure. Three of the most promising therapeutic options for recurrent implantation failure include immune therapies such as peripheral blood mononuclear cells, platelet rich plasma and subcutaneous granulocyte-colony stimulating factor.

Read the full text here.

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders.